Property Value
dbo:abstract
  • Jerini AG was a pharmaceutical company based in Berlin, Germany, which focused on the discovery and development of novel peptide-based drugs. Using a proprietary technology platform, Peptides-to-Drugs (P2D), Jerini pursued disease indications for which limited, inadequate, or no treatment options exist. As a result, Jerini established a drug pipeline composed of its own programs as well as others in collaboration with partners. Jerini's commercialization strategy was to market new drugs in niche indications independently and in larger indications with partners. Jerini was acquired by Shire plc in 2008.Jerini started operations in 1994. Jerini's subsidiaries Jerini US Inc. and JPT Peptide Technologies GmbH, provider of peptides and peptide microarrays, were acquired by Theracode GmbH, Mainz in 2009. Jerini was financed with venture capital provided by TVM and HealthCap. It went public on the Prime Standard of the Frankfurt Stock Exchange (JI4), and had raised a total of over 130 million Euro in public and private financing to date. (en)
dbo:foundationPlace
dbo:foundingYear
  • 1994-01-01 (xsd:date)
dbo:location
dbo:numberOfEmployees
  • 139 (xsd:integer)
dbo:product
dbo:thumbnail
dbo:wikiPageEditLink
dbo:wikiPageExternalLink
dbo:wikiPageExtracted
  • 2017-04-17 11:06:47Z (xsd:date)
dbo:wikiPageHistoryLink
dbo:wikiPageID
  • 6588551 (xsd:integer)
dbo:wikiPageLength
  • 4221 (xsd:integer)
dbo:wikiPageModified
  • 2017-02-23 14:25:20Z (xsd:date)
dbo:wikiPageOutDegree
  • 24 (xsd:integer)
dbo:wikiPageRevisionID
  • 767021642 (xsd:integer)
dbo:wikiPageRevisionLink
dbp:foundation
dbp:homepage
dbp:keyPeople
  • Adi Hoess, Chief Commercial Officer (en)
  • Berndt Modig, Chief Financial Officer (en)
  • Jens Schneider-Mergener, CEO (en)
  • Jochen Knolle, Chief Scientific Officer, Head of R & D (en)
dbp:location
  • Berlin, Germany (en)
dbp:logo
dbp:name
  • Jerini AG (en)
dbp:numEmployees
  • 139 (xsd:integer)
dbp:products
dbp:wikiPageUsesTemplate
dct:subject
rdf:type
rdfs:comment
  • Jerini AG was a pharmaceutical company based in Berlin, Germany, which focused on the discovery and development of novel peptide-based drugs. Using a proprietary technology platform, Peptides-to-Drugs (P2D), Jerini pursued disease indications for which limited, inadequate, or no treatment options exist. As a result, Jerini established a drug pipeline composed of its own programs as well as others in collaboration with partners. (en)
rdfs:label
  • Jerini (en)
owl:sameAs
foaf:depiction
foaf:homepage
foaf:isPrimaryTopicOf
foaf:name
  • Jerini AG (en)
is dbo:wikiPageRedirects of
is foaf:primaryTopic of